Action potential clamp and chloroquine sensitivity of mutant Kir2.1 channels responsible for variant 3 short QT syndrome

Journal of Molecular and Cellular Cardiology

Volumn 47, Issue 5, 2009, Pages 743-747

  El Harchi, Aziza ^a   McPate, Mark J ^a   Zhang, Yi hong ^a   Zhang, Henggui ^b   Hancox, Jules C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Antiarrhythmic; Arrhythmia; Chloroquine; KCNJ2; Kir2.1; QT interval; Short QT syndrome; Sudden death

Indexed keywords

CHLOROQUINE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; MUTANT PROTEIN; PROTEIN INHIBITOR;

ACTION POTENTIAL; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG SENSITIVITY; HEART ARRHYTHMIA; IC 50; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN VARIANT; SHORT QT SYNDROME; SUDDEN DEATH; TEMPERATURE; WHOLE CELL;

ACTION POTENTIALS; ANIMALS; ANTIRHEUMATIC AGENTS; ARRHYTHMIAS, CARDIAC; CHLOROQUINE; CHO CELLS; CRICETINAE; CRICETULUS; ELECTROPHYSIOLOGY; HUMANS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS, INWARDLY RECTIFYING;

CRICETULUS GRISEUS;

EID: 68349152899     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2009.02.027     Document Type: Article

References (17)

1. Schimpf R., Borggrefe M., and Wolpert C. Clinical and molecular genetics of the short QT syndrome. Curr. Opin. Cardiol. 23 (2008) 192-198
2. Priori S.G., Pandit S.V., Rivolta I., Berenfeld O., Ronchetti E., Dhamoon A., et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ. Res. 96 (2005) 800-807
3. Gaborit N., Le Bouter S., Szuts V., Varro A., Escande D., Nattel S., et al. Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. J. Physiol. 582 (2007) 675-693
4. Kr inactivation by mutation in KCNH2: a link to arrhythmogenesis in short QT syndrome. Cardiovasc. Res. 67 (2005) 498-509
5. + channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 °C. Biochem. Biophys. Res. Commun. 334 (2005) 441-449
6. Wolpert C., Schimpf R., Giustetto C., Antzelevitch C., Cordeiro J., Dumaine R., et al. Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J. Cardiovasc. Electrophysiol. 16 (2005) 54-58
7. + channels involved in variant 1 short QT syndrome. J. Mol. Cell. Cardiol. 41 (2006) 563-566
8. + channel inhibition by disopyramide in patients with a short QT-1 syndrome: a pilot study. J. Cardiovasc. Electrophysiol. 18 (2007) 1157-1160
9. + channel, Kir2.1. J. Physiol. 548 (2003) 361-371
10. ten Tusscher K.H., Noble D., Noble P.J., and Panfilov A.V. A model for human ventricular tissue. Am. J. Physiol, Heart Circ. Physiol. 286 (2004) H1573-H1589
11. + currents in repolarization. Circ. Res. 82 (1998) 63-81
12. + current. Circ. Res. 94 (2004) 1332-1339
13. + channel Kir2.1. J. Physiol. 493 (1996) 643-649
14. Sánchez-Chapula J.A., Salinas-Stefanon E., Torres-Jácome J., Benavides-Haro D.E., and Navarro-Polanco R.A. Blockade of currents by the antimalarial drug chloroquine in feline ventricular myocytes. J. Pharmacol. Exp. Ther. 297 (2001) 437-445
15. Rodríguez-Menchaca A.A., Navarro-Polanco R.A., Ferrer-Villada T., Rupp J., Sachse F.B., Tristani-Firouzi M., et al. The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 1364-1368
16. + currents by antimalarial drugs in stably transfected HEK293 cells. Eur. J. Pharmacol. 484 (2004) 41-48
17. Mzayek F., Deng H., Mather F.J., Wasilevich E.C., Liu H., Hadi C.M., et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin. Trials 2 1 (2007) e6